Ambroxol Hydrochloride Injection
Function and Efficacy
Mucosolvan has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thus significantly promoting expectoration and improving respiratory conditions. When treated with Mucosolvan, the patient's mucus secretion can be restored to normal. Coughing and sputum volume are usually significantly reduced, and the surfactant of the respiratory mucosa thus exerts its normal protective function.
Ingredients
Ambroxol hydrochloride (also known as ambroxol hydrochloride). Excipients: citric acid monohydrate, disodium hydrogen phosphate dihydrate. Sodium chloride, water for injection, nitrogen.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Ambroxol hydrochlorideIngredients |
It has the characteristics of promoting mucus elimination and dissolving secretions, which can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, improve breathing conditions, restore normal mucus secretion, reduce coughing and sputum volume, and enable the surfactant of the respiratory mucosa to play its normal protective function. More |
23828-92-4 | 38 | |
| Citric acid monohydrateExcipients |
Mucosolvan has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thus significantly promoting expectoration and improving respiratory conditions. When treated with Mucosolvan, the patient's mucus secretion can be restored to normal. Coughing and sputum volume are usually significantly reduced, and the surfactant of the respiratory mucosa thus exerts its normal protective function. More |
5949-29-1 | 38 | |
| Disodium hydrogen phosphate dihydrateExcipients |
Mucosolvan has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thus significantly promoting expectoration and improving respiratory conditions. When treated with Mucosolvan, the patient's mucus secretion can be restored to normal. Coughing and sputum volume are usually significantly reduced, and the surfactant of the respiratory mucosa thus exerts its normal protective function. More |
10028-24-7 | 7 | |
| Sodium chlorideExcipients |
Mucosolvan has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thus significantly promoting expectoration and improving respiratory conditions. When treated with Mucosolvan, the patient's mucus secretion can be restored to normal. Coughing and sputum volume are usually significantly reduced, and the surfactant of the respiratory mucosa thus exerts its normal protective function. More |
7647-14-5 | 43 | |
| NitrogenExcipients |
Mucosolvan has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thus significantly promoting expectoration and improving respiratory conditions. When treated with Mucosolvan, the patient's mucus secretion can be restored to normal. Coughing and sputum volume are usually significantly reduced, and the surfactant of the respiratory mucosa thus exerts its normal protective function. More |
7727-37-9 | 6 |
Indication
1. Applicable to acute and chronic lung diseases accompanied by abnormal sputum secretion and poor expectoration function. For example, acute exacerbation of chronic bronchitis, asthmatic bronchitis and expectoration treatment of bronchial asthma. Preventive treatment of postoperative pulmonary complications. 2. Treatment of infant respiratory distress syndrome (IRDS) in premature infants and newborns.
Usage and Dosage
1. Adults and children over 12 years old: 2-3 times a day, 1 ampoule each time, slow intravenous infusion; 2. In severe cases, it can be increased to 2 ampoules each time. 3. Children aged 6-12 years: 2-3 times a day, 1 ampoule each time. 4. Children aged 2-6 years: 3 times a day, 1/2 ampoule each time. 5. Children under 2 years old: 2 times a day, 1/2 ampoule each time. 6. All are slow intravenous infusions. Treatment of infant respiratory distress syndrome (IRDS): 1. The total daily medication is calculated based on the infant's weight, 30 mg/kg, divided into 4 doses. 2. A syringe pump should be used for administration, and the intravenous injection time should be at least 5 minutes. 3. This injection can also be mixed with glucose, fructose, saline or Ringer's solution for intravenous drip. 4. This product (pH5.0) cannot be mixed with other solutions with a pH greater than 6.3, because the increase in pH will lead to the precipitation of the free base of this product.
Adverse Reactions
This product is usually well tolerated. Mild upper gastrointestinal adverse reactions have been reported (mainly heartburn, indigestion and occasional nausea and vomiting). Allergic reactions are rare, mainly rash. Severe acute allergic reactions have been reported in rare cases, but their relevance to amino acid bromoxynil hydrochloride is not certain. Such patients are usually allergic to other substances.
Precautions
It should not be used by patients with known allergies to ambroxol hydrochloride or other ingredients of the formula.
Special Population Medication
Precautions for children: See [Usage and Dosage]. Precautions for pregnancy and lactation: Preclinical trials and a large amount of clinical experience after 28 weeks of pregnancy show that there is no adverse effect on pregnancy. However, during pregnancy, especially in the first three months of pregnancy, the drug should be used with caution. The drug can enter breast milk, but the therapeutic dose should have no effect on the baby. Precautions for the elderly: No special precautions.
Drug Interactions
The synergistic treatment of this product with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) can increase the concentration of antibiotics in lung tissue, and there are no reports of clinically relevant adverse reactions when used in combination with other drugs.
Storage
Please store in a sealed container below 30 degrees. Please keep out of the reach of children!
Packaging Specification
4ml:30mg
Validity Period
60 months
Manufacturer
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
-
Founded in:
2001-11-30 -
Address:
Luoqi Road, Linyi High-tech Industrial Development Zone, Shandong Province -
Tax NO.:
913700002658705037 -
Registered Funds:
60.96 million yuan -
Website:
-
Email: